BCM
PEAR

Basso Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Basso Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$1K – 516
2021
Q1 		$1K Buy
+100
New +$966 ﹤0.01% 374

Other funds holding PEAR

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Basso Capital Management's PEAR Position: Q2 2021 in Review

Basso Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2021, closing a stake of 100 shares — an estimated $1K sold.

Basso Capital Management first reported a position in PEAR in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 72 funds tracked by Wall St. Rank hold PEAR as of Q2 2021.

  • Basso Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
  • Basso Capital Management sold 100 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2021, an estimated $1K.
  • Basso Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2021 and held it in 1 quarter.
  • Basso Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $1K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2021.

Based on Basso Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.